• May 30, 2020 

    China NMPA Approves Optune for the Treatment of Newly Diagnosed and Recurrent GlioblastomaBookmark

    George Lundberg, MD

    Press release from Novocure curated by Editor in Chief George Lundberg, MD, who notes: 

    Chinese doctors managing one the most difficult tumors to treat, glioblastoma (GBM), now have another approved option, Optune, after favorable clinical trial results. The method has been previously approved by the U.S. Food and Drug Administration.

    Go to full article published by Novocure on Business Wire.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020 

    Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian CancerBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Clinical trial results have shown a 13-month overall survival benefit from maintenance therapy—treatment to prevent or delay recurrence—with olaparib for advanced ovarian cancer.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020 

    FDA Approves Frontline Atezolizumab for PD-L1–High NSCLCBookmark

    George Lundberg, MD

    Article from OncLive curated by Editor in Chief George Lundberg, MD, who notes:

    The U.S. Food and Drug Administration (FDA) has approved another new drug for people with metastatic non-small cell lung cancer (NSCLC) tumors that have high levels of a protein called PD-L1.

    Go to full article published by OncLive.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020 

    No OS Boost With Opdivo in Recurrent GlioblastomaBookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 25, 2020 

    What’s New in Immunotherapy for Non-Small Cell Lung Cancer?

    Emma Shtivelman, PhD

    Chemotherapy was once the only treatment option for metastatic non-small cell lung cancer (NSCLC). But five years ago, immunotherapy—treatment that boosts a patient’s own immune system to fight cancer—came on the scene. In 2015, the U.S. Food and Drug Administration (FDA) approved the drug nivolumab (brand name Opdivo) as next-line treatment for NSCLC after chemotherapy. Today, new immunotherapy options continue… Read more »

  • May 2, 2020 

    FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian CancerBookmark

    George Lundberg, MD

    Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

    This FDA announcement is a welcome one for patients afflicted by epithelial ovarian cancer that has spread.

    Go to full article published by the FDA.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • April 22, 2020 

    FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast CancerBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Based upon clinical trial results compared to controls, the U.S. Food and Drug Administration (FDA) has approved additional uses for the drug tucatinib (brand name Tukysa) in combination with trastuzumab and capecitabine.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • April 21, 2020 

    5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the Two Techniques to Optimize the Extent of Resection in Glioblastoma SurgeryBookmark

    George Lundberg, MD

    Research paper from Neurosurgery curated by Editor in Chief George Lundberg, MD, who notes: 

    The best chance a patient has for survival with glioblastoma is the extent to which the tumor is initially removed surgically. The tools discussed in this study can help the surgeon maximize extirpation.

    Go to full paper published in Neurosurgery.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • April 9, 2020 

    FDA Approves Pancreatic Cancer Drug Treatment After It Was Shown to Increase Progression Free SurvivalBookmark

    George Lundberg, MD

    Article from Good News Network curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved the use of Lynparza (olaparib) for treating  stage 4 pancreatic cancer patients with hereditary BRCA mutation who have not progressed on platinum therapy. A clinical trial showed prolongation of progression free survival in this subset of patients.

    Go to full article published by Good News Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • April 9, 2020 

    New Pancreatic Cancer Therapies Extending LivesBookmark

    George Lundberg, MD

    Article from WebMD curated by Editor in Chief George Lundberg, MD, who notes: 

    An aggressive 3-part approach may offer hope for some patients with stage 4 pancreatic cancer.

    Go to full article published by WebMD.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.